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Abstract  19 
Human soluble Epoxide Hydrolase (hsEH) is an enzyme responsible for the inactivation of 20 
bioactive epoxy fatty acids, and its inhibition is emerging as a promising therapeutical 21 
strategy to target hypertension, cardiovascular disease, pain and insulin sensitivity. Here, we 22 
uncover the molecular bases of hsEH inhibition mediated by the endogenous 15-deoxy-Δ12,14-23 
Prostaglandin J2 (15d-PGJ2). Our data reveal a dual inhibitory mechanism, whereby hsEH can 24 
be inhibited by reversible docking of 15d-PGJ2 in the catalytic pocket, as well as by covalent 25 
locking of the same compound onto cysteine residues C423 and C522, remote to the active 26 
site. Biophysical characterisations allied with in silico investigations indicate that the 27 
covalent modification of the reactive cysteines may be part of a hitherto undiscovered 28 
allosteric regulatory mechanism of the enzyme. This study provides novel insights into the 29 
molecular modes of inhibition of hsEH epoxy-hydrolytic activity and paves the way for the 30 
development of new allosteric inhibitors.  31 
  32 
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Introduction 33 
Human soluble Epoxide Hydrolase (hsEH) is a cytosolic enzyme which modulates the 34 
metabolism of bioactive epoxy fatty acids (EpFAs), by converting them into their 35 
corresponding vicinal diols1,2. In mammals, the enzyme is composed of two structurally 36 
distinct domains connected by a proline-rich linker3. Whilst the N-terminal domain exerts 37 
phosphatase activity on glycerophospoholipids and lysophosphatidic acids4–6, the hydrolytic 38 
activity on EpFAs resides in the C-terminal domain (CTD)7–9. This hydrolysis involves a SN2 39 
nucleophilic attack by D335 on the least hindered carbon atom of the epoxide, followed by 40 
water-mediated release of the alkyl-enzyme intermediate, assisted by D496 and H524. 41 
Residues Y383 and Y466 provide support to catalysis through the establishment of hydrogen 42 
bonds with the oxygen of the epoxy ring1. The catalytic site of hsEH CTD has been described 43 
as an ‘L-shaped’ tunnel with both ends open to the solvent. The catalytic triad (D335, D496 44 
and H524) is located at the vertex of the ‘L’, edged by two hydrophobic regions at both sides, 45 
namely the F267 Pocket and W334 Niche1,3. The EpFA substrates of hsEH CTD are 46 
oxygenated derivatives of arachidonic, linoleic and α-linoleic acids, which possess anti-47 
inflammatory, antihyperalgesic and vasoactive properties, and whose bioavailability has been 48 
linked to cardiovascular, inflammatory and neurodegenerative diseases, nociception and 49 
diabetes10–12. Of these substrates, the best characterised are the epoxyeicosatrienoic acids 50 
(EETs)2,13,14, which are endothelial-derived hyperpolarising factors able to induce dilation of 51 
small-size arteries in vascular districts of kidneys, heart, lung and brain15–18. EETs exhibit 52 
other beneficial properties, such as anti-platelet aggregation, anti-inflammatory effects, 53 
analgesic activity, apoptotic inhibition, vascular smooth muscle cell anti-migratory action and 54 
cardio-protection16,19. Given that hydrolysis of EETs to the corresponding diols, namely 55 
dihydroxyeicosatrienoic acids, leads to largely inactive compounds13, hsEH inhibition has 56 
emerged as a promising strategy to enhance the bioavailability of EETs and reap their 57 
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protective and beneficial effects. The search for hsEH inhibitors has been the object of 58 
intense research for almost 30 years, leading to the discovery of more than a thousand 1,3-59 
disubstituted urea antagonists, and related amides, carbamates, esters and carbonates, able to 60 
inhibit hsEH20,21. Of the numerous compounds developed, only few have reached clinical 61 
trials. The 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), and its salts and esters22, 62 
induced increased microvessel flux in healthy and heart failure human subjects, but its 63 
efficacy at a systemic level was not conclusively established23. The inhibitor AR9281 (1-64 
adamantanyl-3-(1-acetylpiperidin-4-yl) urea), reduced systolic blood pressure in Angiotensin 65 
II-induced hypertensive mice, ameliorated renal injury recovery and improved vascular 66 
function24. The results of phase II clinical trials in patients with impaired glucose tolerance 67 
and mild to moderate hypertension were however inconclusive25,26. The compound 68 
GSK2256294 ((1R,3S)-(cis)-N-{[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-{[4-methyl-69 
6-(methylamino)-1,3,5-triazin-2-yl]amino} cyclohexanecarboxamide) showed suppression of 70 
pulmonary inflammation in mice exposed to cigarette smoke27, though the results from phase 71 
II clinical trials with healthy volunteers, moderately obese smokers and mild to moderate 72 
hypertensive patients are still pending28,29. Given that no inhibitors characterised thus far has 73 
reached the clinic, research into new hsEH antagonists remains active.  74 
At endogenous level, sEH activity was thought to be exerted largely by controlling protein 75 
expression level17. A breakthrough in the field was the discovery of a first endogenous ligand, 76 
namely 15-deoxy-Δ12,14-Prostaglandin-J2 (15d-PGJ2), able to efficiently modulate the activity 77 
of murine sEH30. 15d-PGJ2 is a product of the arachidonic acid metabolism, generated in 78 
vitro by macrophages in response to inflammatory stimuli, and identified in vivo in 79 
atherosclerotic plaques31, as well as in plasma during the resolution phase of 80 
inflammation32,33. As an α/β-unsaturated ketone electrophilic lipid, 15d-PGJ2 reacts in 81 
Michael additions with cysteine residues of proteins34, including Kelch-like ECH-Associated 82 
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Protein 1 (Keap1)35, negative regulator of the Nuclear Factor (Erythroid-Derived-2)-like 2 83 
(Nrf2)36, peroxisome proliferator-activated receptor gamma (PPARγ)35,37 and IκB kinase 84 
(IKK)38,39, modulating their function and/or cellular localisation. Charles et al30 showed that 85 
15d-PGJ2 induces vasodilation of coronary vasculature of ex vivo perfused murine hearts in a 86 
sEH-dependent manner. Given that a knock-in C521S-sEH murine model showed resistance 87 
to 15d-PGJ2-mediated vasodilation, the cysteine residue C521 (C522 in human sequence 88 
numbering) was identified as the target of the Michael addition by the electrophilic lipid. The 89 
molecular details of this inhibition though remained unclear. 90 
By using a combined biochemical and biophysical approach, this study elucidates the 91 
mechanism of human sEH inhibition by 15d-PGJ2. hsEH was found to be covalently 92 
modified by 15d-PGJ2 on two cysteine residues located outside the catalytic pocket, one of 93 
which, C423, was to our knowledge discovered here for the first time, as it is not present in 94 
the murine ortholog. Most importantly, we revealed that the covalent modification of both 95 
cysteines is accompanied by a conformational change of the protein, thereby uncovering a 96 
hitherto unknown allosteric mechanism of sEH inhibition. In addition to the allosteric control, 97 
our investigations show that 15d-PGJ2 is also able to inhibit hsEH orthosterically, by 98 
interacting in a reversible non-covalent manner with residues within the catalytic pocket. We 99 
therefore propose a dual molecular model of 15d-PGJ2-mediated hsEH inhibition, whereby 100 
the ligand can bind reversibly to hsEH impeding the catalysis or adduct covalently the 101 
enzyme on allosteric sites causing a conformational switch towards an inactive state.  102 
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Results  103 
15d-PGJ2 covalently modifies two cysteines in hsEH CTD  104 
To investigate whether human sEH C-terminal Domain (hsEH CTD) was covalently 105 
modified by the endogenous electrophilic lipid 15d-PGJ2, as reported for the murine 106 
ortholog30, Electrospray Ionisation Mass Spectrometry (ESI-MS) experiments were 107 
performed. Upon incubation of the human protein with the prostaglandin, three main peaks 108 
were detected (Fig. 1a): whilst one matched the free protein molecular mass (39496.4 Da), 109 
the other two showed a deconvoluted mass of 39810.3 and 40141.5 Da, corresponding to the 110 
addition respectively of 312.1 and 645.1 Da. These peaks were assigned to the covalent 111 
complexes formed between hsEH CTD and 15d-PGJ2 molecules (316.4 Da), revealing that 112 
the protein is modified in vitro by either one or two units of prostaglandin. No signal other 113 
than the apoprotein was observed upon treatment with the reversible antagonist AUDA or 114 
buffer alone. Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) revealed 115 
two distinct sites of adduction for 15d-PGJ2: C522 (Fig. 1b), located at the entrance of the 116 
F267 Pocket, which corresponds to the murine counterpart C521 previously identified30; and 117 
C423 (Fig. 1c), a residue conserved only in Primates (see below), located outside the active 118 
site, approximately 10 Å away from the edge of the F267 Pocket. 119 
We next asked whether these two modification sites on the human sEH protein were 120 
equivalent. To evaluate the kinetics of adduction on the two cysteines, we followed the 121 
appearance overtime of the covalent adducts, comparing the behaviour of wild-type hsEH 122 
CTD (WT) with that of single C423S and C522S mutants, and C423S/C522S double mutant, 123 
replacing the reactive cysteines with serines. The proteins incubated with 15d-PGJ2 were 124 
analysed via HPLC reverse phase chromatography at various time points (Fig. 1d, 125 
Supplementary Fig. 1). The UV elution profiles for wild type (WT), C423S and C522S 126 
proteins showed the presence of additional species that were retained in the reverse phase 127 
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column longer than apoproteins, which were assigned to the covalently modified adducts. 128 
The lack of additional elution peaks for the C423S/C522S mutant corroborated the identity of 129 
the retained species and confirmed that C423S and C522S are the only targets of the Michael 130 
addition of 15d-PGJ2 to hsEH CTD. Deconvolution of HPLC UV traces provided a measure 131 
for the rate of adduct formation overtime, showing that the covalent modification of C423S 132 
and C522S occurs at different rates. Interestingly, the C423S mutant experiences a 133 
considerably lower adduction rate, indicating that C423 reacts with 15d-PGJ2 faster than 134 
C522 (Fig. 1e).  135 
 136 
15d-PGJ2 covalent adduction on C423 and C522 inhibits hsEH  137 
We interrogated the effect of Michael addition of 15d-PGJ2 to C423 and C522 on hsEH CTD 138 
enzymatic activity. To purify the covalent adducts, a bespoke separation strategy via 139 
Benzylthio-Sepharose (BTS) affinity chromatography resin was devised. BTS is able to bind 140 
sEH through interactions between the enzyme’s hydrophobic active site and benzylmercaptan 141 
moieties immobilised onto Sepharose beads40,41. We hypothesised that the modification by 142 
15d-PGJ2 might affect this interaction, possibly through conformational effects (see below). 143 
Upon incubation with 15d-PGJ2, a proportion of the WT, C423S and C522S enzymes was 144 
indeed not retained by the BTS resin (Fig. 2a and Supplementary Fig 2). These flow-through 145 
fractions were unambiguously shown to contain prostaglandin-covalently adducted proteins 146 
that failed to bind to the resin (Fig. 2b): their UV spectra in fact revealed a three-peak 147 
absorbance profile, with the expected aromatic amino acids absorbance at 280 nm and two 148 
additional peaks at 250 and 330 nm, which matched the UV spectrum of 15d-PGJ2 (Fig. 2b, 149 
Supplementary Fig. 3a). Not only did this indicate a successful separation of prostaglandin-150 
modified proteins from the apoproteins, but also suggested that in the covalently adducted 151 
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species the active site of the enzyme is somewhat altered, becoming unable to bind to the 152 
benzylmercaptan compound. 153 
The epoxy-hydrolytic activity of the purified hsEH proteins covalently modified by 15d-PGJ2 154 
was then evaluated using a fluorimetric-based assay42 (Fig. 2c, Supplementary Fig. 3b). 155 
These experiments showed that the hsEH-15d-PGJ2 adducts experienced a significant 156 
reduction of enzymatic activity when compared to apoproteins, with the single modification 157 
of C423S and C522S mutants inhibiting the enzyme to a lesser extent. This suggests that the 158 
two cysteine residues are not equivalent in their ability to impair enzyme activity when 159 
covalently modified, and that their inhibitory effect is somewhat cumulative.  160 
Although the covalent modification on C522 and C423 inhibits hsEH CTD, these cysteines 161 
are not located within the enzyme’s catalytic pocket, nor are they involved in the mechanism 162 
of epoxide hydrolysis. With C522 proximal to the entrance of the catalytic tunnel on the F267 163 
pocket, the covalently bound 15d-PGJ2 moiety at this site may block access of the substrate to 164 
the active pocket through steric hindrance. Nonetheless, this is not a plausible explanation for 165 
C423, which is further away from the catalytic crevice. To understand in greater depth the 166 
molecular bases of this inhibitory mechanism, and prompted by the behaviour of the 15d-167 
PGJ2 adducts failing to bind the BTS column, we next performed circular dichroism (CD) 168 
analysis (Fig. 2d, Supplementary Fig. 3c). Far-UV CD profiles of WT-, C423S- and C522S-169 
15d-PGJ2 covalent adducts differed from the spectra of the respective apoproteins in overall 170 
shape and molar ellipticities, thus reflecting changes in protein secondary structure content 171 
upon covalent binding. Deconvolution analyses of CD data indicate that thiol modification by 172 
15d-PGJ2 is accompanied by a decrease in α-helical and an increase of β-strand content, and 173 
that double adduction of both cysteine residues results in a somewhat cumulative effect 174 
(Table 1). This indicates that the Michael addition of 15d-PGJ2 to both C423 and C522 175 
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induces conformational changes in the enzyme, that could account for the impairment of 176 
hydrolytic activity.  In other words, an allosteric mechanism of inhibition43.  177 
 178 
15d-PGJ2 reversibly binds the catalytic site of hsEH CTD  179 
To elucidate the basis of the 15d-PGJ2-mediated inhibitory mechanism, we pursued a 180 
structural approach. First, we solved the structure of apo hsEH CTD by X-ray 181 
crystallography, and our results were found to be in excellent agreement with previously 182 
deposited structures of the full-length enzyme9, with an RMSD of 0.257 Å on all CTD heavy 183 
atoms. The apoprotein crystallised in space group I2, with two hsEH CTD molecules in the 184 
asymmetric unit forming a homodimer (Fig. 3a, Supplementary Fig. 4, Table 2). To obtain 185 
the structure of the covalent adducts, hsEH CTD crystals were subjected to soaking with 15d-186 
PGJ2 (Table 2). Although one unit of the prostaglandin was found bound to each monomer of 187 
hsEH CTD in the crystals, it was not covalently attached to either C522 or C432, but instead 188 
was accommodated in the F267 Pocket of the catalytic site (Fig. 3b, 3c). This structure 189 
therefore depicts an orthosteric non-covalent interaction between 15d-PGJ2 and hsEH CTD. 190 
Superposition of the apo and holo crystal structures gave an RMSD on all heavy atoms of 191 
0.198 Å, indicating a high similarity of the two structures. Minor changes were observed in 192 
two regions proximal to the F267 Pocket (Supplementary Fig. 5).  193 
In the reversible non-covalent complex with 15d-PGJ2, the di-unsaturated aliphatic chain and 194 
the ring of the ligand threaded inside the F267 pocket, whilst the mono-unsaturated aliphatic 195 
chain was found partially protruding outside the catalytic site (Fig. 3d). The di-unsaturated 196 
aliphatic chain established van der Waals contacts with protein residues of a hydrophobic 197 
surface formed by F267, P268, Y383, L408, L417, and V498. The oxygen of the 15d-PGJ2 198 
ring engaged in a hydrogen bond with the backbone nitrogen of F497. F497 also made van 199 
der Waals contacts with the ligand benzylic moiety. Moreover, the hydroxyl group of S412 200 
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and the backbone nitrogen of H524 were found at a relatively short distance (around 3 Å) 201 
from the cyclopentenonyl oxygen of 15d-PGJ2, suggesting that they may participate with 202 
F497 in positioning the prostaglandin ring. Further van der Waals contacts were established 203 
between Cβ and Cγ of H524 and 15d-PGJ2 di-unsaturated aliphatic chain, S412 and the 204 
cyclopentenonyl ring of the prostaglandin, and S415, L417, and M419 and the mono-205 
unsaturated aliphatic chain of the ligand.  206 
The finding that 15d-PGJ2 was able to bind reversibly in the enzyme catalytic pocket was not 207 
anticipated, thus Saturation-Transfer Difference NMR (STD-NMR) experiments were 208 
performed to support the crystallographic data. The 1H-NMR spectrum of the 15d-PGJ2 (Fig. 209 
4a) was assigned from deposited chemical shift data44 and a 1H-NMR spectrum of hsEH CTD 210 
was recorded (Supplementary Fig. 6a) as control. The off-resonance (I0) and on-resonance 211 
(ISAT) spectra (Fig. 4b) were acquired on the hsEH CTD and 15d-PGJ2 mixture, in parallel 212 
with a control experiment performed by irradiating a solution of prostaglandin alone 213 
(Supplementary Fig. 6b). Spectra subtraction of the protein-ligand mixture revealed 214 
saturation of several protons of the prostaglandin, and their STD amplification factor (ASTD) 215 
values were plotted against the irradiation time, showing the expected hyperbolic profile (Fig. 216 
4c). Epitope mapping indicates a stronger interaction of the di-unsaturated aliphatic chain of 217 
15d-PGJ2 with hsEH CTD in solution (Fig. 4d), in agreement with the crystallographic 218 
structure. Overall, the combined crystallography and solution approach revealed that 15d-219 
PGJ2 is able to bind non-covalently within the catalytic pocket of hsEH CTD. 220 
Next, we sought to examine the impact of 15d-PGJ2 reversible interaction on hsEH enzymatic 221 
activity. To assess solely the reversible orthosteric effect of the ligand, the C423S/C522S 222 
mutant protein was used in spectrofluorimetric assays, revealing a half maximal inhibitory 223 
concentration (IC50) of 30.03 ± 0.61 µM and an inhibitory constant (Ki) of 8.56 ± 0.17 µM 224 
(Fig. 5a and Supplementary Fig. 7a). Minimising the incubation time and therefore the 225 
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formation of covalent adduct(s), the IC50 and Ki of the 15d-PGJ2 for the WT CTD were also 226 
measured, as a control (Fig. 5b and Supplementary Fig. 7). These values (IC50 45.69 ± 5.40 227 
µM; Ki 13.03 ± 1.54 µM) were largely in agreement with the ones obtained for the 228 
C423S/C522S mutant, indicating that both experiments are describing the same molecular 229 
process. Based on these data, we concluded that 15d-PGJ2 can inhibit hsEH both in the 230 
reversible and in the covalent state, in other words both orthosterically and allosterically.  231 
 232 
15d-PGJ2 adduction destabilises the hsEH CTD active site  233 
Whereas the orthosteric inhibition by 15d-PGJ2 was characterised at the atomic level by the 234 
crystal structure described above, a molecular description was lacking for the allosteric effect 235 
mediated by covalent modifications at C522 and C423. Despite numerous attempts, no 236 
satisfactory X-ray crystallography diffraction data for the covalent adducts were obtained. In 237 
parallel, we undertook an in silico approach to predict the conformational effects of 238 
prostaglandin addition at the two cysteine sites. SwissDock identified several putative 239 
binding poses of 15d-PGJ2 surrounding C423 and C522. Those with the shortest distance 240 
between the ligand electrophilic carbon atoms and the nucleophilic thiols of the reactive 241 
cysteine residues were selected (Fig. 6a) and used as input for AlloSigMA, a structure-based 242 
statistical mechanical model tool which measures difference in configurational work exerted 243 
by binding of an allosteric ligand on a per-residue allosteric free energy (Δgi) decomposition, 244 
using normal mode analyses45. Increased (positive sign) and decrease (negative sign) Δgi 245 
correspond respectively to predicted local destabilisation and stabilisation of the 246 
configurational energy (Δgi) associated with the calculated modes of the ‘rigidified’ 247 
(perturbed) binding site. When the C423 site was analysed, a decrease of Δgi was shown for 248 
Y383, one of the two epoxide-positioners involved in the hydrolysis (Fig. 6b and 249 
Supplementary Fig. 8). Conversely, the catalytic residue D335 exhibited a considerable 250 
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increase in Δgi, suggesting that 15d-PGJ2 binding may induce the repositioning of this key 251 
residue impairing the catalysis. Moreover, a milder increase in Δgi was observed for the other 252 
epoxide positioner Y466, as well as for some of the residues of the W336 niche, suggesting 253 
an induced conformational change of this side of the binding pocket upon perturbation of the 254 
C423 site. When the C522 site was investigated, the entire catalytic triad (D335, D496, 255 
H524) showed a decrease in Δgi, whilst the two epoxide positioners (Y383, Y466) and the 256 
residues from both W336 niche (W336, M469) and F267 Pocket (F267, L408, M419, V498) 257 
exhibited a Δgi increase (Fig. 6c). This would suggest that the ligand binding on the C522 site 258 
induces a stabilisation of the catalytic triad, inducing a large conformational change of the 259 
binding pocket, and possibly leading to transition towards an inactive state. When both C423 260 
and C522 sites were analysed in conjunction, an enhanced stabilisation of the catalytic triad 261 
was associated with a large-amplitude motion of the binding pocket, as showed by the greater 262 
destabilisation of the epoxide positioners, as well as the W336 niche and F267 Pocket (Fig. 263 
6d). Altogether, our in silico analysis supports an allosteric regulation of 15d-PGJ2 mediated 264 
by its covalent binding to the two reactive cysteine residues C423 and C522. 265 
  266 
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Discussion 267 
Previous studies proposed that 15d-PGJ2 inhibits murine sEH by covalent modification of 268 
C52130. In this study we revealed that 15d-PGJ2 exerts inhibition of the human sEH ortholog 269 
by binding both non-covalently in the catalytic pocket and covalently to reactive cysteine 270 
residues, one of which, namely C423, was not characterised in earlier work. Our X-ray 271 
crystallographic structure places 15d-PGJ2 in the active site, resulting in reversible enzyme 272 
inhibition with a Ki in the low micromolar range. The position of 15d-PGJ2 in the outer 273 
region of the F267 Pocket suggests that inhibition is achieved largely by impairment of 274 
substrate binding to the active site, although contacts between the ligand and the catalytic 275 
residue H524, as well as the epoxy-positioner Y383, do not exclude the possibility of a 276 
reduced availability of crucial amino acids involved in the hydrolytic reaction. In addition to 277 
this reversible orthosteric inhibition, our studies corroborated that hsEH activity is hindered 278 
by covalent modification of reactive cysteine residues, although contrary to the murine 279 
enzyme30, two residues were unveiled in the human ortholog by our investigations, namely 280 
C423 and C522. We demonstrated that, although the covalent modification of a single 281 
cysteine site results in inhibition, the adduction to both residues leads to a greater decrease in 282 
the enzymatic activity of hsEH CTD. A major outcome of this work is that C423 was 283 
discovered as a modification site in human. Interestingly, this residue is conserved only in 284 
Primates, suggesting that the modulation of soluble Epoxide Hydrolase differs within the 285 
tetrapod lineage (Fig. 7a). Intriguingly, our data appear to indicate that C423 is modified by 286 
15d-PGJ2 at faster rate of adduction than C522 and that this leads to a greater level of enzyme 287 
inhibition, although the relative importance of these two residues in an in vivo setting remains 288 
to be established. 289 
Taken together, our data suggest a dual mode of inhibition of hsEH CTD by 15d-PGJ2 (Fig. 290 
7b), that could be modelled as an extension of the ‘dock-and-lock’ mechanism previously 291 
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described for another 15d-PGJ2 target, namely PPARγ46. This model envisages that the 292 
reversible ‘docking’ of 15d-PGJ2 in the catalytic pocket would be followed by the covalent 293 
‘locking’ on the two reactive cysteines C423 and C522. Both states lead to reduction of 294 
enzymatic activity, though the fast reversible interaction may facilitate and drive the slower 295 
covalent addition (reversible-driven covalent addition), which by its nature would have a 296 
prolonged and more potent effect overtime. The position of C423 and especially C522 around 297 
the catalytic pocket may support this hypothesis. In this context it may be plausible that the 298 
docking-to-locking (or reversible-to-covalent) switch is regulated by the oxidation redox 299 
status of the reactive cysteine residues and other environmental clues that may change the 300 
reactivity and/or availability of their thiol groups. Nonetheless, a direct and consequential 301 
link between the reversible and irreversible mode of inhibition of 15d-PGJ2 may not 302 
necessarily exist, providing instead alternative ways to inhibit the enzyme.  303 
In our X-ray crystallographic structure, the prostaglandin was found inside the active site, 304 
specifically occupying the F267 Pocket of the L-shaped catalytic tunnel. The majority of sEH 305 
orthosteric inhibitors are 1,3-disubstituted urea antagonists, and variations thereof, able to 306 
position themselves in and around the vertex region, impeding substrate access to the 307 
catalytic triad20,47 (Fig. 7c). Although numerous sEH antagonist were found to target the F267 308 
region20,48,49, we identified a continuous binding surface for 15d-PGJ2, involving residues 309 
S412, S415, L417, and M419. These unique binding features allow the delineation of a novel 310 
interacting surface, at the very entrance of the catalytic site (Fig. 7c), which could potentially 311 
be exploited as an anchoring region in the design of new orthosteric hsEH inhibitors with 312 
different chemical scaffolds. More importantly though, because of its ability to undergo 313 
Michael addition with allosteric residues C522 and C423, 15d-PGJ2 could represent a 314 
putative lead molecule for the development of new covalent allosteric drugs for hsEH, whose 315 
advantages include higher specificity, increased biochemical efficacy, a preference for 316 
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shallow binding pockets, lower toxicity and lower administration doses, high enough for the 317 
drug molecule to reach each target protein and persist until the body has produced more 318 
protein50,51. Furthermore, the prospect of allosteric inhibition would potentially circumvent 319 
the historical drawbacks associated with orthosteric inhibitors, none of which has succeeded 320 
to in clinical trials, despite intense and sustained efforts20,21,26,28,29.  321 
In this study we provide new critical evidence on the mechanism by which the covalent 322 
modification of 15d-PGJ2 on C522 and C423 inhibits hsEH CTD. Notably, these cysteine 323 
residues are not located within the active site, nor are in any way involved in the epoxide 324 
hydrolysis, thereby indicating an allosteric modulation of the enzyme via post-translation 325 
modification. Our CD studies show that 15d-PGJ2 adduction on both C423 and C522 is 326 
accompanied by conformational changes in hsEH CTD, possibly affecting the active site. 327 
This would in turn disrupt substrate accessibility and/or render substrate binding less 328 
favorable thermodynamically. Consistent with this, upon 15d-PGJ2 covalent modification the 329 
enzyme was no longer capable of binding the high affinity benzylmercaptan compound 330 
immobilised onto the BTS resin. The biophysical characterisation was backed up by in silico 331 
studies that were able to predict allosteric communication between the C423 and C522 332 
binding surfaces and the catalytic site, particularly affecting the conformation of the two 333 
epoxide positioners and various other residues in both W336 niche and F267 Pocket. A 334 
picture is emerging in which the covalent modification of these cysteines remote from the 335 
catalytic site elicits conformational and dynamics changes of the hsEH CTD towards an 336 
inactive state, although the detailed mode of regulation awaits structure determination of 337 
C522/C423-adducted covalent complex(es). Notably, in the case of C522, its location in the 338 
vicinity of the entrance of the catalytic tunnel does not rule out the possibility that the 339 
allosteric regulation may be coupled with a steric hindrance effect also contributing to 340 
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inhibition. Given its location remote from the catalytic pocket, the same cannot be argued for 341 
C423 (Fig. 7c).  342 
From a physiological perspective, it could be envisaged that 15d-PGJ2 may regulate hsEH 343 
enzyme activity in various tissues where the prostaglandin and the hydrolase co-localise, such 344 
as astrocytes, macrophages, and small size arteries14,17,34. Interestingly, 15d-PGJ2 possesses 345 
anti-inflammatory activities31,34,52 and its production increases in response to inflammatory 346 
stimuli33. Although further studies are needed to correlate the levels of 15d-PGJ2 production 347 
and hsEH activity, one may speculate that enhanced prostaglandin levels may imply a greater 348 
inhibition of sEH, which in turn would augment the bioavailability of EETs and other epoxy-349 
fatty acids with anti-inflammatory properties, possibly contributing synergically to the 350 
resolution of the inflammation and inducing cardio- and neuroprotection16,53,54. 351 
In conclusion, our research unveiled that hsEH CTD undergoes a dual mechanism of 352 
inhibition with the endogenous 15d-PGJ2, mediated by covalent and non-covalent 353 
interactions. The latter reversible interaction uncovered a putative new orthosteric binding 354 
surface to be exploited for the design of new drugs. Although the molecular details of hsEH 355 
structural perturbation upon covalent adduction are yet to be fully understood, our data taken 356 
together strongly support a hitherto undiscovered allosteric mechanism of hsEH regulation. 357 
Altogether, this study provides new insight in the regulatory mechanism of the epoxy-358 
hydrolytic activity of hsEH and paves the way for new modes of sEH inhibition for 359 
improving cardiovascular health, inflammation and diabetes. 360 
  361 
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Methods 362 
Plasmid construction and site directed mutagenesis  363 
The EPHX2 (T230-M555 – hsEH CTD) cDNA was cloned in the bacterial expression vector 364 
pET3a, as described previously41. Single mutants C423S and C522S were generated with the 365 
Q5® Site-Directed Mutagenesis Kit (NEB). The double mutant C423S/C522S 366 
(C423S/C522S) was produced through two subsequent cycles of mutagenesis using the same 367 
kit. The mutagenic primers (Sigma), were designed with the NEB changer webtool according 368 
to the kit specifications (C423S_R: 5’ GCATAAAGTCAGTGAAGCGGG 3’; C423S_F: 5’ 369 
ATGGATAAAACACTCTCATCG 3’; C522S_R: 5’ CATTGAGGACAGTGGGCACTG 3’; 370 
C522S_F: 5’ TGTCCCCTTTTCAGGTGG 3’). Successful mutagenesis was confirmed by 371 
sequencing (Eurofins MWG). 372 
Protein expression and purification  373 
The hsEH CTD and its mutants were expressed in Ros2TM(DE3) (EMD Millipore) and 374 
purified as described previously for WT41.  375 
Electrospray Ionisation Mass-Spectrometry (ESI-MS)  376 
hsEH CTD protein sample was dialysed overnight at 4ºC in 25 mM HEPES, 300 mM NaCl, 377 
10% glycerol, pH 7.4, 10 μM tris(2-carboxyethyl)phosphine (TCEP) (reaction buffer). The 378 
protein was incubated overnight at 4ºC 1:8 v/v (molar ratio) with 15d-PGJ2 (BertinPharma – 379 
dissolved in PBS), AUDA (Sigma – dissolved in PBS), and PBS as control. At the end of the 380 
incubation period, the reaction was quenched by adding 5 mM DTT, and excess ligand was 381 
removed by buffer exchange on an Amicon Ultra-0.5 mL centrifugal Filter (Merck) at 382 
10000×g and 4ºC. The samples were diluted in 0.1% formic acid at a final concentration of 383 
60 μg mL-1, and injected directly into the maXis instrument (Bruker) via a motorised pump 384 
with at a flow rate of 10-50 μL min-1. The spectra were recorded for 3-30 minutes at a 385 
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spectral rate of 1 Hz, with an end plate offset of -500 V, a capillary voltage of -4500 V, a 386 
nebuliser pressure of 3.0 bar, and a tuned ISCID energy between 80 and 110 eV. The spectra 387 
obtained were deconvoluted using microTOF software (Bruker), performing a maximum 388 
entropy analysis. 389 
Liquid chromatography - tandem Mass Spectrometry (LC-MS/MS)  390 
50 μg of hsEH CTD, incubated overnight at 4°C with 15d-PGJ2 (1:8 v/v protein-to-ligand 391 
molar ratio), was separated by SDS-PAGE on a 20% bis-acrylamide gel, for 30 minutes at 392 
100 V (according to Laemmli protocol55). The protein bands were cut in discrete pieces and 393 
digested overnight with 5 μg of trypsin (Sigma-Aldrich) at room temperature, after an initial 394 
incubation at 37ºC for 2 hours. Peptides were extracted from the gel by a series of acetonitrile 395 
and aqueous washes, and the extract was lyophilised and resuspended in 10 μL of 50 mM 396 
ammonium bicarbonate. Chromatographic separation of the peptides was performed using an 397 
EASY NanoLC system (ThermoFisher Scientific), by reversed phase chromatography on a 398 
75 μm C18 column, using a three-step linear gradient of acetonitrile in 0.1% formic acid. The 399 
gradient was delivered to elute the peptides at a flow rate of 300 nL min-1 over 60 minutes. 400 
The eluate was ionised by electrospray ionisation using an Orbitrap Velos Pro (ThermoFisher 401 
Scientific), operating under Xcalibur v2.2. The instrument was programmed to acquire in 402 
automated data-dependent switching mode, selecting precursor ions based on their intensity 403 
for sequencing by collision-induced fragmentation using a Top20 CID method. MS/MS 404 
analyses were conducted using collision energy profiles that were chosen based on the mass-405 
to-charge ratio (m/z) and the charge state of the peptide. Raw mass spectrometry data were 406 
processed into peak list files using Proteome Discoverer (ThermoScientific; v1.4). Processed 407 
raw data were analysed using the Mascot 2.2.06 (Matrix Science) search algorithm against 408 
“All Taxonomy” in the Uniprot database and an in-house database containing the protein 409 
sequence of interest, assuming the digestion enzyme trypsin. Mascot was searched with a 410 
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fragment ion mass tolerance of 0.80 Da and a parent ion tolerance of 20 ppm. 15d-PGJ2 411 
modification of cysteine residues was specified in Mascot as variable modifications. Scaffold 412 
4.7.5 (Proteome Software Inc) was used to validate MS/MS based peptide and protein 413 
identifications. High stringency filters of 95% confidence interval (CI) for minimum protein 414 
and 0% CI for peptide values was applied. A 95% probability CI in the MOWSE scoring 415 
algorithm in Mascot was applied. Protein probabilities were assigned by the Protein Prophet 416 
algorithm56. The analysis yielded 42 unique peptide fragments (88% sequence coverage), of 417 
which two were unambiguously modified by 15d-PGJ2. 418 
High-Pressure Liquid Chromatography (HPLC) analyses  419 
hsEH CTD WT, C423S, C522S, and C423S/C522S proteins were dialysed overnight at 4ºC 420 
in reaction buffer (see ESI-MS section), and then incubated at 4ºC 1:8 v/v (molar ratio) with 421 
15d-PGJ2 (dissolved in PBS). After 30 minutes, 2.5 hours, or 20 hours, the reaction was 422 
quenched by adding 5 mM DTT and immediately flash-frozen in liquid nitrogen. 2.5 μg of 423 
the protein samples were mixed with 10 mM TRIS-HCl pH 7.5, to be loaded, using an 424 
Agilent 1200 HPLC system, on a reversed phase column (ACE 5 C18-300, 250 × 4.6 mm). 425 
The species were eluted with a 48-60% gradient of acetonitrile and 0.1% TFA, over 12 426 
minutes at 1 mL min-1. The traces obtained were deconvoluted with Fityk software57 and the 427 
peaks integrated with a Pearson VII function. The areas under the peaks were used to back 428 
calculate the amount of adduct observed at each time point of the reaction and extrapolate the 429 
rate of adduction.   430 
Purification of covalent adducts  431 
To purify the covalent adducts, we designed a tailored Benzylthio-Sepharose (BTS) affinity 432 
chromatography protocol. Apo-hsEH CTD binds BTS via interactions between the enzyme’s 433 
hydrophobic binding pocket and benzylmercaptan moieties immobilised onto Sepharose 434 
beads40,41, whilst covalently adducted counterparts do not interact with the resin and were 435 
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collected in the column flow-through fractions.  15d-PGJ2-hsEH CTD covalent adducts were 436 
prepared as follows. 0.5 mg of WT, C423S, C522S, and C423S/C522S proteins were dialysed 437 
overnight at 4ºC in 25 mM 3-(N-morpholino)propanesulfonic acid (MOPS) pH 7.4, 75 mM 438 
NaCl, 5% glycerol, 10 μM TCEP (binding buffer), and then incubated at 4ºC 1:8 v/v (molar 439 
ratio) with 15d-PGJ2 (dissolved in PBS) or binding buffer (as control). After overnight 440 
incubation, the mixtures were loaded onto 500 μL of BTS resin in gravity columns (prepared 441 
in-house41), previously equilibrated in binding buffer. After 15 minutes incubation at room 442 
temperature, the flow-through was collected and the resin washed 5 times with 500 μL of 443 
binding buffer. 500 μL of elution buffer (binding buffer containing 1 mM 2-benzoyl-3-444 
phenyloxirane) were added onto the resin to incubate for 15 minutes before elution. The 445 
protein samples were eluted with 5×500 μL elution buffer and collected. SDS-PAGE 446 
analyses were carried out to identify the proteins in the fractions. The flow-through and 447 
elution fractions containing protein were pooled together and dialysed overnight at 4ºC in 20 448 
mM TRIS-HCl pH 7.4, 100 mM NaCl, 2% glycerol, 10 μM TCEP, concentrated to 0.5 449 
mg/mL and flash frozen in liquid nitrogen. 450 
hsEH CTD enzymatic activity measurements  451 
The activity of the isolated proteins was measured using a spectrofluorometric method which 452 
monitors hsEH-mediated hydrolysis of the synthetic substrate 3-phenyl-cyano(6-methoxy-2-453 
naphthalenyl)methyl ester-2-oxiraneacetic acid (PHOME), through the detection of the final 454 
fluorescent product 6-methoxy-2-naphthaldehyde (6M2N)58. Protein samples were diluted to 455 
a final concentration of 50 nM in 25 mM TRIS-HCl pH 7.4 in a black 96-well polystyrene 456 
microtiter plate (Thermo Scientific). A fresh 0.4 mM solution of the synthetic substrate 457 
PHOME was prepared in DMSO and diluted 1:40 v/v in the 96-well plate. The measurements 458 
of fluorescence units (RFUs) generated by the hsEH CTD-mediated hydrolysis of PHOME 459 
were carried out in quadruplicate for 20 minutes using a POLARstar Omega (BMG Labtech), 460 
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with the following setup: excitation/emission wavelengths 330/460 nm, gain 750, detection 461 
every 45 seconds, and temperature at 30°C. Each sample of three different protein 462 
preparations was tested in triplicate. Quantification of the epoxy-hydrolytic rate was carried 463 
out using a conversion curve reporting the fluorescence of 6M2N, as a function of the 464 
fluorophore concentration, as described previously41.  465 
Ultraviolet–visible and Circular Dichroism  spectroscopy  466 
Ultraviolet–visible (UV) and Circular Dichroism (CD) spectra were acquired at 25ºC on an 467 
Applied Photophysics Chirascan Plus spectrometer (Leatherhead, UK). 10 mm (500-220 nm) 468 
and 0.5 mm (260-190 nm) Quartz Suprasil rectangular cells (Starna Scientific Ltd) were 469 
employed. The instrument was flushed continuously with pure evaporated nitrogen 470 
throughout the experiment. The following parameters were set: 2 nm spectral bandwidth, 1 471 
nm step size, and 1 second instrument time per point. Light-scattering adjustment and buffer 472 
subtraction were applied to the UV spectra of each sample, using the Chirascan Pro-Data 473 
Software (APL). UV and CD spectra of the covalent adducts were recorded at a final 474 
concentration of 0.15 mg/mL (calculated using the A280nm value obtained upon light-475 
scattering correction and the extinction coefficient computed using the ProtParam tool within 476 
ExPASy Portal59). The far-UV CD spectra were smoothed with a window factor of 4 using 477 
the Savitzky-Golay method for better presentation, then corrected for concentration and 478 
pathlength, and expressed in terms of mean residue ellipticity (MRE). Protein secondary 479 
structure content was assessed using the SELCON 3 algorithm (data set 4), embedded in the 480 
Dichroweb webtool60.  481 
X-ray crystallography  482 
Recombinant hsEH CTD was crystallised by vapour diffusion, in sitting drops containing 100 483 
nL of protein solution (hsEH CTD concentration 10 mg mL-1, in 50 mM HEPES, 300 mM 484 
NaCl, 10% glycerol, 3 mM DTT, pH 7.4), and 200 nL of precipitation buffer (22.5% PEG 485 
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3350, 0.2 M malic acid), equilibrated against a 20 μL reservoir of precipitant buffer at 4ºC. 486 
After ~5 days, cubic crystals of around 30 × 30 × 30 μm were obtained. Following soaking in 487 
precipitant buffer containing 25% ethylene glycol and flash cooling in liquid nitrogen, 488 
crystals yielded diffraction data to 2.6 Å at the Diamond Light Source, Didcot, UK. The 489 
diffraction data were reduced, scaled, and merged using XIA2 software61. The crystals 490 
belonged to space group I121, with unit cell parameters a = 88.22, b = 80.14, and c = 104.70 491 
Å. Crystals were then soaked in precipitation buffer containing 10 mM 15d-PGJ2 (Cayman 492 
Chemical, USA), incubated for 15 minutes, cryoprotected with 25% ethylene glycol and flash 493 
frozen in liquid nitrogen. Diffraction yielded a resolution of 2 Å. Upon reduction, merging, 494 
and scaling with XIA2 software61, the structure was solved by molecular replacement in 495 
PHENIX62, using the deposited PDB file 3ANS63. The density map was explored and built in 496 
COOT64, and the structure was refined iteratively by automatic structure refinement using the 497 
software Refmac5 within CCP4 suite65. The 15d-PGJ2 molecule was added into the final 498 
stages of refinement. Data reduction and refinement statistics are reported in Table 2.  499 
Half maximal inhibitory concentration (IC50) measurements  500 
The inhibitory potency of 15d-PGJ2 was measured using an end-point adaptation of the 501 
PHOME spectrofluorometric method described above. Recombinant hsEH CTD WT and 502 
C423S/C522S were reduced with 10 µM TCEP on ice for 15 minutes, then diluted in a 96-503 
well polystyrene microtiter plate in freshly prepared 25 mM TRIS-HCl pH 7.4 to a final 504 
concentration of 15 nM. The proteins were then incubated at room temperature for 10 505 
minutes with 15d-PGJ2 (diluted 1:40 v/v to obtain increasing concentration between 0.1 and 506 
250 μM). A fresh 0.4 mM solution of PHOME was prepared in DMSO and diluted 1:40 v/v 507 
in the 96-well plate. A POLARstar Omega (BMG Labtech) was used to measure the relative 508 
fluorescence units (RFUs) for 20 min, using the same setting as above. Measurements were 509 
performed in four replicates, for a total of four technical repeats. The readouts at 12 minute 510 
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reaction times were corrected for the background signal generated by the PHOME auto-511 
hydrolysis, converted into nmol of 6M2N (6-methoxy-2-naphthaldeyde) and plotted as 512 
percentage of activity against the Log10 of 15d-PJG2 concentration58. The data points were 513 
fitted with “log(inhibitor) vs. response - variable slope” in GraphPad, and further considered 514 
only if R2 was ≥ 0.9. Inhibitory constants (Ki) values were calculated using the Cheng-515 
Prusoff equation66. 516 
Saturation-transfer difference NMR 517 
Saturation-transfer difference NMR (STD-NMR) is a technique for the detection of reversible 518 
binding interactions between small molecule ligands and macromolecular interactors in 519 
solution67. NMR spectra were recorded on a Bruker AVANCE-500 NMR spectrometer 520 
(Bruker). Both hsEH CTD and 15d-PGJ2 samples were prepared in 50 mM HEPES, 300 mM 521 
NaCl, 10% glycerol, 0.1 mM TCEP, pH 7.4, 10% D2O. After recording the 1H-NMR-I0 522 
spectra of both hsEH CTD (10 μM) and 15d-PGJ2 (1000 μM), STD-NMR experiments were 523 
performed at 293.15 K, mixing protein and ligand at a 1/100 v/v molar ratio, with the pulse 524 
sequence stddiffesgp.3, using a train of Gaussian pulses of 50 ms duration at a power level of 525 
86 Hz, spaced by a delay of 1 ms. The irradiation power of the selective pulses was set to 526 
(γ/2π)B1 = 86 Hz. Selective pre-saturation of the protein was achieved by a train of Gauss-527 
shaped pulses of 50 ms length each, separated by a 1 ms delay. Irradiation was performed at -528 
0.55 ppm (and -30 ppm as reference) for a total saturation time spanning between 0.5 to 6 529 
seconds. The subtraction of the saturated spectra from the reference spectra was performed 530 
using TopSpin3.2, after identical processing and phasing. Control experiments were 531 
performed by irradiating the ligand in isolation (same experimental setting as for above): no 532 
STD signal was detected, confirming that the saturation observed in presence of the protein 533 
was due to the interaction between hsEH CTD and 15d-PGJ2. The STD effect was quantified 534 
in terms of amplification factor (ASTD), calculated with the following equation: 535 
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ASTD = 
ISTD
I0
 · 
[15d-PGJ2]
[hsEH CTD]
 
where ISTD/I0 corresponds to the ratio between STD (ISTD) and off-resonance (I0) signals, 536 
while [15d-PGJ2]/[hsEH CTD] is the ligand-to-protein molar ratio68. Percentage ASTD values 537 
were calculated by normalising for the greatest ASTD value observed (C20) and used to model 538 
the hsEH CTD – 15d-PGJ2 epitope mapping interaction68.  539 
Microscale thermophoresis  540 
hsEH CTD protein was dialysed in 25 mM HEPES, pH 7.4, 300 mM NaCl, 2% glycerol, 10 541 
µM TCEP and labelled in dark with the amino-reactive blue dye, following the Monolith NT 542 
Protein Labelling kit protocol (NanoTemper Technologies). 100 nM of labelled enzyme were 543 
incubated for 10 minutes at room temperature with 15d-PGJ2 at concentrations ranging 544 
between 0.0038 and 125 µM (1:1 serial dilution). Microscale thermophoresis (MST) 545 
experiments were performed at 20% of LED power and 40% of MST power with a Monolith 546 
NT.115 (NanoTemper Technologies). Data analysis was performed using the MO.control 547 
software (NanoTemper Technologies), fitting the auto-normalised data in manual mode. KD 548 
values were obtained by fitting with dose-response equations implemented in the MO.control 549 
software.  550 
AlloSigMA analyses  551 
AlloSigMA is a structure-based statistical mechanical model tool which estimates the per-552 
residue allosteric free energies (Δgi) associated with an effector binding. Particularly, Δgi > 0 553 
and Δgi < 0 correspond to increased and decreased free energies associated to changes in 554 
stability due to allosteric signalling. More precisely, these values quantify variations in 555 
configurational work exerted on a specific residue, as a consequence of changes in the 556 
measured configurational ensemble upon ligand binding (by normal mode analysis). The 557 
ligand binding process is simulated in this framework by rigidifying (‘perturbing’) the 558 
residues involved in the binding. The free energy variation associated with such perturbation 559 
is approximated by a summation over the normal modes45. AlloSigMA analyses were carried 560 
out after identifying putative 15d-PGJ2 binding sites around the two reactive cysteine residues 561 
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C423 and C522 using SwissDock69. The docking of 15d-PGJ2 (ZINC05972962) was 562 
performed in accurate mode on the apoprotein crystal structure solved in this study, centring 563 
the docking region of interest on the Chain A sulphur atoms of C423 and C522, and allowing 564 
3 Å side chains flexibility. The poses were further considered only when the ΔG obtained 565 
was lower than -5 kcal mol-1. Once the binding sites were defined, the per-residue allosteric 566 
free energy (Δgi) calculations were carried out using the AlloSigMA web-server70, perturbing 567 
the putative C423 and C522 binding sites (in isolation and together). The results were 568 
presented in graphics coloured in red and blue scales to indicate respectively stabilised and 569 
destabilised residues.  570 
Statistics and reproducibility 571 
The ESI-MS experiments, HPLC purifications, UV and CD analyses, IC50 values 572 
measurements, STD-NMR experiments, MST analyses, and enzymatic activity measurements 573 
were carried out in at least three biological replicates. The statistical significance for the 574 
enzymatic activity experiments was obtained by comparing the enzymatic rates with one-575 
tailed homoscedastic t-test and reported in plots as average ± SEM. The statistical 576 
significance was reported as follows: * as 0.05 < p ≤ 0.005, ** as 0.005 < p ≤ 0.0005, *** p < 577 
0.0005. 578 
 579 
 580 
  581 
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Figure Legends 806 
Fig. 1 Analysis of the covalent interaction between hsEH CTD and 15d-PGJ2. a ESI-MS 807 
experiments. Grey and black arrows indicate the free and covalently modified hsEH CTD 808 
respectively. The electrophilic carbon atoms of 15d-PGJ2 are indicated by asterisks. b LC-809 
MS/MS evidence of C423 modification. A peptide with m/z 1154.092+ was assigned through 810 
the identification of ions b2-b4, b6-b14, and y5-y17. The direct assignment of the 811 
modification on both b2- and y17-ions was strong evidence of modification of C423. c LC-812 
MS/MS evidence of C522 modification. The peptide exhibited a m/z of 781.894+. Its sequence 813 
was assigned through the detection of b3-b6, b8, and y2-y12 ions. The b6 ion modification 814 
allowed the direct identification of C522 adduction. d HPLC separation of the covalent 815 
complexes. The traces were collected at three different time points, upon incubation of hsEH 816 
CTD and 15d-PGJ2. For clarity, the chromatograms of the free proteins are reported in 817 
Supplementary Fig. 1. e 15d-PGJ2 rate of adduction. Rates were calculated from 818 
deconvolution of the HLPC traces shown in D, as described in the Methods. The mutant 819 
C423S showed a considerably lower rate of adduction to C522, suggesting that the kinetics of 820 
modification of the two residues are different. Data presented as average ± SEM of n = 4 WT, 821 
n = 3 C522, and n = 3 C423S. (Source data available in Supplementary Data 1).  822 
Fig. 2 Analyses of 15d-PGJ2-hsEH CTD covalent complexes. a Purification of 15d-PGJ2-823 
hsEH CTD covalent adducts. SDS-PAGE analysis of the BTS purification of the proteins 824 
when incubated with either buffer (control) or 15d-PGJ2 (MWM: molecular weight marker, 825 
FT: flow-through fraction; EL: elution fraction). All the proteins bound to the BTS resin in 826 
the control treatment with buffer alone. Upon treatment with 15d-PGJ2, a fraction of the WT, 827 
C423S and C522S enzymes was not retained by the resin and was collected in the flow-828 
through. The C423S/C522S mutant interacted with the BTS in all conditions. Full uncropped 829 
gels are reported in Supplementary Fig. 2. b UV analyses of the covalent adducts. The figure 830 
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reports the UV spectra of the BTS fractions collected either in the flow-through or in the 831 
elution fractions. The peaks at 250 and 330 nm confirmed 15d-PGJ2 adduction to the proteins 832 
collected in the BTS flow-through (from panel A). c Comparative enzymatic activity 833 
analysis. The enzymatic activity of hsEH covalent adducts and apoproteins were measured 834 
with a spectrofluorimetric assays. The comparison showed a significant reduction in 835 
hydrolytic activity for the covalent complexes (ND: non-determined, as the C423S/C522S did 836 
not generate any adduct). The asterisks refer to one-tailed homoscedastic t-test (apoprotein 837 
vs. adducts), and the significance is indicated as follows: * as 0.05 < p ≤ 0.005, ** as 0.005 < 838 
p ≤ 0.0005, *** as p < 0.0005. Data presented as average ± SEM of n = 6 WT, n = 6 C522, 839 
n = 5 C423S, and n = 5 C423S/C522S. (Source data available in Supplementary Data 2). d 840 
CD analyses. Comparison of the CD spectra of the apoproteins (WT, C423S and C522S) and 841 
the corresponding 15d-PGJ2 covalent adducts revealed a conformational rearrangement upon 842 
15d-PGJ2 modification (see Table 1). Spectroscopic and enzymatic analyses of the other 843 
fractions collected in the purifications are reported in the Supplementary Fig. 3.   844 
Fig. 3 X-ray crystallographic structure of the 15d-PGJ2-hsEH CTD complex. a 845 
Crystallographic symmetry. The crystallographic homodimer is represented as a cartoon 846 
model (chain A and B in light blue and salmon red respectively), with the ‘L’-shaped 847 
catalytic site in mesh. b Electron density of the 15d-PGJ2 bound to hsEH CTD. The 2Fc-Fo 848 
map was contoured at 1 sigma. c 15d-PGJ2 binding site. The ‘L-shaped’ catalytic site of 849 
hsEH CTD is represented with a three-colours code: the F267 Pocket in magenta; the W336 850 
Niche in cyan; the ‘L’ vertex formed by the catalytic D335 and the epoxide positioners Y363 851 
and Y466 are represented in blue. d Overall 15d-PGJ2 interaction with hsEH CTD. The 852 
amino acids involved in van der Waals interaction are depicted in brown, while those forming 853 
hydrogen bonds with 15d-PGJ2 are in dark cyan. C423 and C522 are highlighted in orange, 854 
and the reactive electrophilic C13 and C15 atoms of the ligand are indicated by asterisks.  855 
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Fig. 4 Saturation-transfer difference nuclear magnetic resonance (STD-NMR) experiments. a 856 
1H-NMR spectrum of 1 mM 15d-PGJ2 and resonance assignment. b Comparison between I0 857 
(black) and ISAT (red) spectra. The difference spectrum (green) upon 6 seconds irradiation 858 
confirmed the reversible interaction between hsEH CTD and 15d-PGJ2 in solution. STD 859 
values were not corrected by T1. c STD amplification factor (ASTD) vs. irradiation time plot. 860 
The plot reports the curve for four representative signals with different magnitude. d hsEH 861 
CTD – 15d-PGJ2 interaction epitope mapping. The colour-map reports the percentage ASTD 862 
values as follows: pink ≤ 33.3%; 33.4% < salmon ≤ 66.6%; red > 66.7 %.  863 
Fig. 5 IC50 measurement of 15d-PGJ2 for hsEH CTD C423S/C522S (a) and WT (b). Data 864 
presented as average ± SEM of n = 6 WT and n = 4 C423S/C522S. Supplementary Fig. 7 865 
reports the raw data used to build these IC50 curves as well as the Michaelis–Menten kinetics 866 
curves utilised to extrapolate the KM value for PHOME. This value was then used in the 867 
Cheng–Prusoff equation to obtain Ki for 15d-PGJ2, as described in the methods. KD 868 
measurements by microscale thermophoresis analysis is reported in Supplementary Fig. 7e 869 
and 7f.  870 
Fig. 6 In silico analyisis of the allosteric communication induced by perturbation of the 871 
reactive cysteine residues of hsEH CTD. a Binding poses of 15d-PGJ2 at the predicted C423 872 
(left) and C522 (right) binding sites. The ligand is depicted in yellow, while the interacting 873 
residues are depicted in brown. b, c, and d AlloSigMA analysis of the perturbation of binding 874 
sites (C423, C522, and C423 and C522 respectively). The top panels show the cartoon model 875 
of hsEH CTD, coloured according to the predicted Δgi (blue: destabilization – Δgi ≤ -0.2 876 
kcal/mol; red: stabilisation – Δgi ≥ 0.2 kcal/mol). The bottom panels depict the surface 877 
representation, with the perturbed binding sites in green. The full Δgi profiles are reported in 878 
Supplementary Fig. 8. 879 
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Fig. 7 Analysis of sEH binding modes for 15d-PGJ2. a Protein sequence alignment. 880 
Alignment of sEH amino acid sequences of different species, highlighting C423 and C522 in 881 
the top and bottom panel respectively. The red boxes highlight the reactive cysteine residues. 882 
The secondary structure reported above the alignments refers to the human apo sEH structure. 883 
The histograms represent the conservation score calculated by Jalview71 (*: full conservation, 884 
+: full properties conservation). b Proposed dock-and-lock binding mechanism. In a first fast 885 
step, 15d-PGJ2 docks non-covalently in the hsEH CTD binding site (docked state). This is 886 
followed by the formation of a covalent complex (locked state), and this step is characterized 887 
by a slower kinetics. c 15d-PGJ2 binding position compared to previously characterised 888 
orthosteric inhibitors 4XH, CDU, S0J. The surfaces represent the Phe267 Pocket (magenta), 889 
the Vertex (blue) and the Trp334 Niche (cyan), while residues C423 and C522 are reported in 890 
orange. The superposition herein reported was performed using PDBs 1EK247, 3WKC72, and 891 
5AI649.  892 
 893 
 894 
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Table 1 
CD data deconvolution. Secondary structure content analyses indicate a decrease in α-helical 
and an increase in β-strand content upon modification. 
 
 
 
WT 
 α-helices β-strands Turns unordered 
adducts 22.5% 35.5% 21.9% 29.6% 
apoprotein 33.4% 17.3% 22% 29.5% 
C423S 
 α-helices β-strands Turns unordered 
adduct 22.5% 24.4% 22.7% 27.3% 
apoprotein 29.2% 18.2% 22.4% 30.6% 
C522S 
 α-helices β-strands Turns unordered 
adduct 26.5% 19.6% 23.0% 29.1% 
apoprotein 32.0% 17.5% 21.2% 29.3% 
Table 2 
Data collection statistics for hsEH CTD in apo-state and complexed to 15d-PGJ2. 
 Apo hsEH CTD Complexed hsEH CTD 
Data collection   
Space group I 1 2 1 I 1 2 1 
Cell dimensions     
    a, b, c (Å) 88.22    80.14   104.70    89.49    79.99    104.54    
    α, β, γ  (°)  90.00    95.39     90.00 90.00    96.78      90.00 
Resolution (Å) 29.60 – 2.60 (2.72-2.60) 29.73 – 2.00 (2.05-2.00) 
Rsym (%) 9.1 (66.4) 9.6 (63.5) 
I / σI 5.7 (2.1) 10.2 (2.3) 
Completeness (%) 99.9 (100.0) 99.2 (91.6) 
Redundancy 5.1 (5.0) 5.0 (4.6) 
   
Refinement   
Resolution (Å) 2.60 2.0 
No. reflections (observed/unique) 114202/22492 244141/48933 
Rwork / Rfree (%) 24.6 / 27.7 17.4 / 21.9  
No. atoms   
    Protein 5086 5103 
    Ligand/ion N/A 46 
    Water 13 226 
B-factors (Å2)   
    Protein 45.5 34.0 
    Ligand/ion N/A 65.3 
R.m.s. deviations   
    Bond lengths (Å) 0.0104 0.0168 
    Bond angles (°) 1.4487 2.0545 
 
 
